文献速递甲状腺疾病

毒性多结节性甲状腺肿:长期甲巯咪唑与放射性碘治疗的随机对照研究

Treatment of Toxic Multinodular Goiter: Comparison of Radioiodine and Long-Term Methimazole Treatment.
PubMed 文献 · Thyroid · 2019-04-23

该随机平行组试验纳入130例未治疗的毒性多结节性甲状腺肿患者,随机接受长期甲巯咪唑或放射性碘治疗,随访60-100个月。甲巯咪唑组96.2%维持甲功正常,仅3.8%出现亚临床甲减;放射性碘组41%甲减、22%甲亢持续或复发、37%甲功正常。长期低剂量甲巯咪唑安全有效,不劣于放射性碘。

要点

  • 长期低剂量甲巯咪唑治疗TMNG安全有效,不劣于放射性碘。
  • 甲巯咪唑组96.2%维持甲功正常,仅3.8%出现亚临床甲减。
  • 放射性碘组41%甲减,22%甲亢持续或复发。

核心结论

  • 长期低剂量甲巯咪唑治疗60-100个月是TMNG安全有效的方法,不劣于放射性碘治疗。

研究设计与样本

  • 随机平行组试验,纳入130例年龄<60岁、未治疗的毒性多结节性甲状腺肿患者,随机分至长期甲巯咪唑组或放射性碘组。
  • 两组随访60-100个月,甲巯咪唑组中位随访72个月,放射性碘组中位随访84个月。
  • 甲巯咪唑组53例、放射性碘组54例完成60-100个月研究。

主要发现

  • 甲巯咪唑组2例(3.8%)出现亚临床甲减,51例(96.2%)维持甲功正常至研究结束。
  • 甲巯咪唑维持甲功正常的剂量在连续治疗第1、3、5年分别为每日6.3±2.0、4.5±0.9、4.1±1.0 mg。
  • 甲巯咪唑组1例肝酶升高、3例皮肤反应,均发生在治疗前3个月;治疗4至100个月无不良反应发生。
  • 放射性碘组经16.7±2.7 mCi 131I治疗后,22例(41%)甲减,12例(22%)甲亢持续或复发,20例(37%)甲功正常。

临床怎么用

  • 对于年龄<60岁的TMNG患者,可考虑长期低剂量甲巯咪唑作为放射性碘之外的治療选择。
  • 长期甲巯咪唑治疗初期需监测肝酶和皮肤反应,后续维持剂量可逐渐降低。

局限性

  • 甲巯咪唑组12例、放射性碘组11例因副作用、选择其他治疗或未随访被排除。
  • 研究仅纳入年龄<60岁患者,随访最长100个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: This study aimed to compare the effectiveness and safety of long-term methimazole (MMI) and radioiodine (RAI) in the treatment of toxic multinodular goiter (TMNG). Methods: In this randomized, parallel-group trial, 130 consecutive and untreated patients with TMNG, aged <60 years, were enrolled and randomized to either long-term MMI or RAI treatment. Both groups of patients were followed for 60-100 months, with median durations of 72 and 84 months in the MMI and RAI groups, respectively. Results: In the MMI and RAI groups, 12 and 11 patients, respectively, were excluded because of side effects, choosing other modes of treatment and not returning for follow-up; 53 and 54 patients, respectively, completed the study for 60-100 months. In the MMI group, two patients (3.8%) experienced subclinical hypothyroidism, and 51 (96.2%) remained euthyroid until the end of study. The dosage of MMI to maintain euthyroidism was 6.3 ± 2.0, 4.5 ± 0.9, and 4.1 ± 1.0 mg daily during the first, third, and fifth years of continuous MMI treatment. One patient had elevated liver enzymes, and three developed skin reactions during the first three months, but no adverse effects from MMI occurred from 4 to 100 months of therapy. In the RAI group, 22 (41%) became hypothyroid, 12 (22%) had persistence or recurrence of hyperthyroidism, and 20 (37%) became euthyroid after 16.7 ± 2.7 mCi 131I. Conclusion: Long-term, low-dose MMI treatment for 60-100 months is a safe and effective method for treatment of TMNG, and is not inferior to RAI treatment.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Azizi F, Takyar M, Madreseh E, et al. Treatment of Toxic Multinodular Goiter: Comparison of Radioiodine and Long-Term Methimazole Treatment. Thyroid. 2019. PMID: 30803411. doi:10.1089/thy.2018.0397

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。